We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more here.Close Me
On the morning of August 21, 2019, the Alcohol and Gaming
Commission of Ontario (AGCO) released its list of the 42 applicants
that were chosen by lottery for new cannabis retail locations
across the province. This was only the initial step in the process,
as those selected are only given an opportunity to apply for a
license, not guaranteed they will be granted one.
Those selected had until 5:00 PM EDT on Wednesday, August 28 to
submit their completed applications and specified
documentation.
According to an update released by the AGCO on August 30, 2019,
of the 42 applicants:
29 submitted their completed applications by the deadline are
now in the process of being reviewed.
12 did not submit the required documents by the deadline, and
per Lottery Rule 14a, were disqualified.
1 applicant, for reasons unspecified in the update, withdrew
from the process.
As a result, 13 applicants that had been previously placed on
the Wait Lists were brought forward and given the opportunity to
submit completed applications for review.
The AGCO is now conducting eligibility evaluations of the
submitted applications, which includes police and background checks
of all the interested parties involved, as well monitoring for
violations of the stringent lottery rules. If it is determined that
any of the applications do not meet the legally mandated
requirements, more applicants from the Wait List will be called
upon to submit applications.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
As previously reported, the Federal Court granted Teva's claim for compensation under section 8 of the Patented Medicines (Notice of Compliance) Regulations relating to Teva's bortezomib product...
On November 12, 2019, the Canadian Securities Administrators issued Multilateral Staff Notice 51-359 — Corporate Governance Related Disclosure Expectations...
The following provides an overview of the many developments regarding biosimilars in Canada (approvals, pending submissions, regulatory, litigation and market access) that have taken place since our last update in June 2018.
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.